Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

British Journal of Cancer (103)
Oncogene (6)
Bone Marrow Transplantation (3)
Nature Reviews Urology (3)
Nature Communications (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (116)
Reviews (5)
Comments & Opinion (2)
Correspondence (2)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biomarkers
Biotechnology
Cancer
Cell biology
Chemical biology
Developmental biology
Diseases
Drug discovery
Ecology
Genetics
Health care
Immunology
Medical research
Molecular biology
Molecular medicine
Oncology
Physiology
Scientific community
Social sciences

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 126 results

Advanced filters: Author: R J Motzer Clear advanced filters

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

G Procopio
E Verzoni
F De Braud
ResearchOpen Access11 Sept 2012
British Journal of Cancer

Volume: 107, P: 1227-1232
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

R J Motzer
B Escudier
M E Gore
ResearchOpen Access21 May 2013
British Journal of Cancer

Volume: 108, P: 2470-2477
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

S Bracarda
T E Hutson
B Escudier
ResearchOpen Access22 Mar 2012
British Journal of Cancer

Volume: 106, P: 1475-1480
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

D M Shaw
N B Connolly
R E Hawkins
ResearchOpen Access06 Feb 2007
British Journal of Cancer

Volume: 96, P: 567-574
Author Correction: Towards individualized therapy for metastatic renal cell carcinoma

Ritesh R. Kotecha
Robert J. Motzer
Martin H. Voss
Amendments and Corrections25 Apr 2019
Nature Reviews Clinical Oncology

Volume: 16, P: 653
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

G M Mead
M H Cullen
M Mason
ResearchOpen Access05 Jul 2005
British Journal of Cancer

Volume: 93, P: 178-184
Prognosis after salvage treatment for unselected male patients with germ cell tumours

A Gerl
C Clemm
W Wilmanns
Research01 Oct 1995
British Journal of Cancer

Volume: 72, P: 1026-1032
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

M Santoni
U De Giorgi
S Cascinu
ResearchOpen Access05 Sept 2013
British Journal of Cancer

Volume: 109, P: 1755-1759
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

A Bamias
K Tzannis
C Bamia
ResearchOpen Access27 Jun 2013
British Journal of Cancer

Volume: 109, P: 332-341
Sunitinib and other targeted therapies for renal cell carcinoma

T Powles
S Chowdhury
T Hutson
ReviewsOpen Access25 Jan 2011
British Journal of Cancer

Volume: 104, P: 741-745
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours

S D Fosså
S P Stenning
P A Cook
ResearchOpen Access11 Jun 1999
British Journal of Cancer

Volume: 80, P: 1392-1399
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

C-F Xu
T Johnson
R J Motzer
ResearchOpen Access19 Feb 2015
British Journal of Cancer

Volume: 112, P: 1190-1198
Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874

SD Fosså
JP Droz
R Sylvester
Research01 Mar 1995
British Journal of Cancer

Volume: 71, P: 619-624
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

L del Puerto-Nevado
F Rojo
J García-Foncillas
ResearchOpen Access01 May 2014
British Journal of Cancer

Volume: 110, P: 2700-2707
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

S Patil
R A Figlin
R J Motzer
ResearchOpen Access08 May 2012
British Journal of Cancer

Volume: 106, P: 1587-1590
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Maeva Dufies
Sandy Giuliano
Gilles Pagès
ResearchOpen Access29 Aug 2017
British Journal of Cancer

Volume: 117, P: 947-953
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

B Escudier
M D Michaelson
B I Rini
ResearchOpen Access13 May 2014
British Journal of Cancer

Volume: 110, P: 2821-2828
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

J-F Rossi
S Négrier
B Berns
ResearchOpen Access31 Aug 2010
British Journal of Cancer

Volume: 103, P: 1154-1162
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

T Eisen
A-B Loembé
I Bondarenko
ResearchOpen Access08 Oct 2015
British Journal of Cancer

Volume: 113, P: 1140-1147
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

D Cella
A G Bushmakin
R J Motzer
ResearchOpen Access12 Jan 2012
British Journal of Cancer

Volume: 106, P: 646-650
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

T E Hutson
R M Bukowski
R J Motzer
ResearchOpen Access16 Jan 2014
British Journal of Cancer

Volume: 110, P: 1125-1132
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

M E Gore
C Szczylik
R Bukowski
ResearchOpen Access18 Jun 2015
British Journal of Cancer

Volume: 113, P: 12-19
Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma

Li et al. show that the TFE3 driver fusion transcriptionally upregulates an OXPHOS programme in translocation renal cell carcinoma that renders this cancer vulnerable to reductive stress, induced by imbalance of reducing equivalents.

Jiao Li
Kaimeng Huang
Srinivas R. Viswanathan
Research06 Feb 2025
Nature Metabolism

Volume: 7, P: 478-492
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

R de Wit
G Stoter
R Sylvester
Research01 Jun 1995
British Journal of Cancer

Volume: 71, P: 1311-1314
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

R de Wit
G Stoter
R Sylvester
Research01 Sept 1998
British Journal of Cancer

Volume: 78, P: 828-832
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

A A M van der Veldt
M R Meijerink
E Boven
ResearchOpen Access09 Feb 2010
British Journal of Cancer

Volume: 102, P: 803-809
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma

F Donskov
N Marcussen
H von der Maase
ResearchOpen Access03 Feb 2004
British Journal of Cancer

Volume: 90, P: 626-631
Cytochrome P450 CYP3A in human renal cell cancer

G I Murray
M C E McFadyen
W T Melvin
ResearchOpen Access12 Mar 1999
British Journal of Cancer

Volume: 79, P: 1836-1842
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial

Based on the S-TRAC results, sunitinib is approved as adjuvant treatment for adult patients at high risk of recurrent RCC following nephrectomy. Here, the authors report the results of an integrated multi-omics tumor analysis of 171 patients from the trial and identify specific molecular subtypes as well as potential new targets.

Robert J. Motzer
Jean-François Martini
Alain Ravaud
ResearchOpen Access10 Oct 2022
Nature Communications

Volume: 13, P: 1-12
Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

G Groenewegen
M Walraven
E Voest
ResearchOpen Access03 Jan 2012
British Journal of Cancer

Volume: 106, P: 284-289
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer

R de Wit
R Sylvester
G Stoter
Research01 Feb 1997
British Journal of Cancer

Volume: 75, P: 432-435
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy

N S Vasudev
V Goh
A R Reynolds
ResearchOpen Access06 Aug 2013
British Journal of Cancer

Volume: 109, P: 1230-1242
RETRACTED ARTICLE: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis

V Damiano
R Rosa
G Tortora
ResearchOpen Access09 Apr 2013
British Journal of Cancer

Volume: 108, P: 1616-1623
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

N A G Lankheet
J S L Kloth
N Steeghs
ResearchOpen Access15 Apr 2014
British Journal of Cancer

Volume: 110, P: 2441-2449
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours

I A McNeish
E J Kanfer
M J Seckl
ResearchOpen Access09 Mar 2004
British Journal of Cancer

Volume: 90, P: 1169-1175
Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours

A J Zurita
J E Diestra
M A Izquierdo
ResearchOpen Access18 Mar 2003
British Journal of Cancer

Volume: 88, P: 879-886
A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma

A Horwich
R T D Oliver
S P Stenning
ResearchOpen Access05 Dec 2000
British Journal of Cancer

Volume: 83, P: 1623-1629
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

B Beuselinck
P Wolter
P Schöffski
ResearchOpen Access06 Nov 2012
British Journal of Cancer

Volume: 107, P: 1665-1671
GAMEC – a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours

J Shamash
T Powles
R T D Oliver
ResearchOpen Access03 Jul 2007
British Journal of Cancer

Volume: 97, P: 308-314
Targeted therapy for metastatic renal cell carcinoma

P H Patel
R S K Chaganti
R J Motzer
ReviewsOpen Access07 Feb 2006
British Journal of Cancer

Volume: 94, P: 614-619
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

J S Waters
C Moss
T Eisen
ResearchOpen Access26 Oct 2004
British Journal of Cancer

Volume: 91, P: 1763-1768
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

D Cella
M D Michaelson
R J Motzer
ResearchOpen Access26 Jan 2010
British Journal of Cancer

Volume: 102, P: 658-664
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?

Darren R Feldman
Robert J Motzer
Dean F Bajorin
Comments & Opinion11 Dec 2007
Nature Clinical Practice Urology

Volume: 5, P: 78-79
Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer

B A Usmani
M Janeczko
D M Nanus
ResearchOpen Access07 Jan 2000
British Journal of Cancer

Volume: 82, P: 550-552
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [¹⁸F]FDG PET

C Bokemeyer
C Kollmannsberger
L Kanz
ResearchOpen Access12 Feb 2002
British Journal of Cancer

Volume: 86, P: 506-511
Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

T Wahlgren
U Harmenberg
B Ljungberg
ResearchOpen Access26 Mar 2013
British Journal of Cancer

Volume: 108, P: 1541-1549
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

D Cella
B Escudier
R Motzer
ResearchOpen Access11 Apr 2013
British Journal of Cancer

Volume: 108, P: 1571-1578
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Patients with cancer undergoing anti-PD-1 immune checkpoint blockade can experience immune-related adverse effects. Wherry and colleagues examined the immunity elicited upon immunization of patients with cancer and report that anti-PD-1 immunotherapy dynamically affects influenza vaccine-induced immune responses.

Ramin Sedaghat Herati
David A. Knorr
E. John Wherry
Research28 Jul 2022
Nature Immunology

Volume: 23, P: 1183-1192
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

H Yu
R Liu
P S Gill
ResearchOpen Access16 Jul 2015
British Journal of Cancer

Volume: 113, P: 616-625
Landmarks in the diagnosis and treatment of renal cell carcinoma

Renal cell carcinoma (RCC) is the most lethal of the common urological cancers, and is increasing in incidence globally. Bhatt and Finelli present a Timeline of landmarks in four centuries of research and treatment of RCC, the most common renal cancer, discussing current therapies and future prospects.

Jaimin R. Bhatt
Antonio Finelli
Reviews12 Aug 2014
Nature Reviews Urology

Volume: 11, P: 517-525

Previous page
page 1
page 2
page 3
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited